Comparative efficacy of cefotetan and clindamycin plus amikacin as antimicrobial prophylaxis for major head and neck surgery

J Chemother. 1991 Apr;3(2):117-20. doi: 10.1080/1120009x.1991.11755465.

Abstract

A total of 41 patients were randomly allocated to receive either cefotetan (total dose, 20 g) or clindamycin (total dose, 12 g) plus amikacin (total dose, 5 g) as perioperative antimicrobial prophylaxis for major head and neck surgery. The two groups were similar in age, male to female ratio, stage of cancer, and the various types of surgery. No patient received radiotherapy or chemotherapy before surgery. The wound infection rate was 4% in the group of patients receiving cefotetan and 0% in the group receiving clindamycin plus amikacin. No major side effects were observed in either group. On the basis of this study a five-day perioperative course with cefotetan may be considered effective antimicrobial prophylaxis in patients undergoing major head and neck oncologic surgery.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Amikacin / therapeutic use*
  • Cefotetan / therapeutic use*
  • Clindamycin / therapeutic use*
  • Cross Infection / drug therapy
  • Cross Infection / prevention & control*
  • Cross Infection / surgery
  • Female
  • Head and Neck Neoplasms / surgery*
  • Humans
  • Male
  • Surgical Wound Infection / drug therapy
  • Surgical Wound Infection / prevention & control*
  • Surgical Wound Infection / surgery

Substances

  • Clindamycin
  • Cefotetan
  • Amikacin